<article title='Chagas_disease'><paragraph><template><target>bots</target><arg name="deny">Monkbot7</arg></template><space/><template><target>Use dmy dates</target><arg name="date">March 2014</arg></template><template><target>featured article</target></template><template><target>Infobox disease</target><arg name="Name"><space/>Chagas disease
</arg><arg name="Image"><space/>Trypanosoma cruzi crithidia.jpeg
</arg><arg name="Caption"><space/>Photomicrograph of [[Giemsa]]-stained ''Trypanosoma cruzi''
</arg><arg name="pronounce"><space/>{{IPAc-en|ˈ|tʃ|ɑː|ɡ|ə|s}}
</arg><arg name="field"><space/>[[Infectious disease (medical specialty)|Infectious disease]]
</arg><arg name="DiseasesDB"><space/>13415
</arg><arg name="ICD10"><space/>{{ICD10|B|57||b|50}}
</arg><arg name="ICD9"><space/>{{ICD9|086}}
</arg><arg name="ICDO"><space/>
</arg><arg name="OMIM"><space/>
</arg><arg name="MedlinePlus"><space/>001372
</arg><arg name="eMedicineSubj"><space/>med
</arg><arg name="eMedicineTopic"><space/>327
</arg><arg name="MeshID"><space/>D014355
</arg></template><bold>Chagas disease</bold>, also known as<space/><bold>American trypanosomiasis</bold>, is a<space/><link><target>tropical disease</target><part>tropical</part></link><space/><link><target>parasitic disease</target></link><space/>caused by the<space/><link><target>protozoa</target><trail>n</trail></link><space/><italics><link><target>Trypanosoma cruzi</target></link></italics>.<extension extension_name='ref' name="WHO2013"></extension><space/>It is spread mostly by insects known as<space/><link><target>Triatominae</target></link><space/>or kissing bugs.<extension extension_name='ref' name="WHO2013"></extension><space/>The symptoms change over the course of the infection. In the early stage, symptoms are typically either not present or mild, and may include fever, swollen<space/><link><target>lymph nodes</target></link>, headaches, or local swelling at the site of the bite.<extension extension_name='ref' name="WHO2013"></extension><space/>After 812 weeks, individuals enter the chronic phase of disease and in 6070% it never produces further symptoms.<extension extension_name='ref' name="Rassi2010"><template><target>cite journal</target><arg name="author">Rassi A, Rassi A, Marin-Neto JA<space/></arg><arg name="title">Chagas disease<space/></arg><arg name="journal">Lancet<space/></arg><arg name="volume">375<space/></arg><arg name="issue">9723<space/></arg><arg name="pages">1388–402<space/></arg><arg name="date">April 2010<space/></arg><arg name="pmid">20399979<space/></arg><arg name="doi">10.1016/S0140-6736(10)60061-X</arg></template></extension><extension extension_name='ref' name="Rassi2012"><template><target>cite journal</target><arg name="author">Rassi A Jr, Rassi A, Marcondes de Rezende J</arg><arg name="title">American trypanosomiasis (Chagas disease)</arg><arg name="journal">Infectious disease clinics of North America</arg><arg name="date">June 2012</arg><arg name="volume">26</arg><arg name="issue">2</arg><arg name="pages">275–91</arg><arg name="pmid">22632639</arg><arg name="doi">10.1016/j.idc.2012.03.002</arg></template></extension><space/>The other 30 to 40% of people develop further symptoms 10 to 30 years after the initial infection,<extension extension_name='ref' name="Rassi2012"></extension><space/>including enlargement of the<space/><link><target>ventricles of the heart</target></link><space/>in 20 to 30%, leading to<space/><link><target>heart failure</target></link>.<extension extension_name='ref' name="WHO2013"></extension><space/>An<space/><link><target>megaesophagus</target><part>enlarged esophagus</part></link><space/>or an<space/><link><target>megacolon</target><part>enlarged colon</part></link><space/>may also occur in 10% of people.<extension extension_name='ref' name="WHO2013"></extension></paragraph><preblock><preline><italics>T. cruzi</italics><space/>is commonly spread to humans and other mammals by the<space/><link><target>hematophagy</target><part>blood-sucking</part></link><space/>&quot;kissing bugs&quot; of the subfamily<space/><link><target>Triatominae</target></link>.<extension extension_name='ref' name="CDC"><template><target>cite web</target><arg name="publisher">Centers for Disease Control (CDC)<space/></arg><arg name="url"><space/>http://www.cdc.gov/dpdx/trypanosomiasisAmerican/<space/></arg><arg name="title">DPDx&nbsp;– Trypanosomiasis, American. Fact Sheet<space/></arg><arg name="accessdate">12 May 2010</arg></template></extension><space/>These insects are known by a number of local names, including:<space/><italics>vinchuca</italics><space/>in Argentina, Bolivia, Chile and Paraguay,<space/><italics>barbeiro</italics><space/>(the<space/><link><target>barber surgeon</target><part>barber</part></link>) in Brazil,<space/><italics>pito</italics><space/>in Colombia,<space/><italics>chinche</italics><space/>in Central America, and<space/><italics>chipo</italics><space/>in Venezuela.<extension extension_name='ref'><template><target>cite book</target><arg name="editor">Maudlin I, Holmes PH, Miles MA</arg><arg name="title">The Trypanosomiases</arg><arg name="date">2004</arg><arg name="publisher">CAB International</arg><arg name="location">Wallingford</arg><arg name="isbn">9780851990347</arg><arg name="page"><space/>[https://books.google.ca/books?id</arg></template></extension><space/>The disease may also be spread through<space/><link><target>blood transfusion</target></link>,<space/><link><target>organ transplantation</target></link>, eating food contaminated with the parasites, and by<space/><link><target>vertical transmission</target></link><space/>(from a mother to her fetus).<extension extension_name='ref' name="WHO2013"></extension><space/>Diagnosis of early disease is by finding the parasite in the blood using a microscope.<extension extension_name='ref' name="Rassi2012"></extension><space/>Chronic disease is diagnosed by finding<space/><link><target>antibodies</target></link><space/>for<space/><italics>T. cruzi</italics><space/>in the blood.<extension extension_name='ref' name="Rassi2012"></extension></preline></preblock><preblock><preline>Prevention mostly involves eliminating kissing bugs and avoiding their bites.<extension extension_name='ref' name="WHO2013"></extension><space/>Other preventative efforts include screening blood used for transfusions.<extension extension_name='ref' name="WHO2013"></extension><space/>A vaccine has not been developed as of 2013.<extension extension_name='ref' name="WHO2013"></extension><space/>Early infections are treatable with the medication<space/><link><target>benznidazole</target></link><space/>or<space/><link><target>nifurtimox</target></link>.<extension extension_name='ref' name="WHO2013"></extension><space/>Medication nearly always results in a cure if given early, but becomes less effective the longer a person has had Chagas disease.<extension extension_name='ref' name="WHO2013"></extension><space/>When used in chronic disease, medication may delay or prevent the development of endstage symptoms.<extension extension_name='ref' name="WHO2013"></extension><space/>Benznidazole and nifurtimox cause temporary side effects in up to 40% of people<extension extension_name='ref' name="WHO2013"></extension><space/>including skin disorders, brain toxicity, and digestive system irritation.<extension extension_name='ref' name="Rassi2010"></extension><extension extension_name='ref' name="Bern"><template><target>cite journal</target><arg name="vauthors">Bern C, Montgomery SP, Herwaldt BL, etal<space/></arg><arg name="title">Evaluation and treatment of chagas disease in the United States: a systematic review<space/></arg><arg name="journal">JAMA<space/></arg><arg name="volume">298<space/></arg><arg name="issue">18<space/></arg><arg name="pages">2171–81<space/></arg><arg name="date">November 2007</arg><arg name="pmid">18000201<space/></arg><arg name="doi">10.1001/jama.298.18.2171</arg></template></extension><extension extension_name='ref' name="Rassi2"><template><target>cite journal</target><arg name="author">Rassi A, Dias JC, Marin-Neto JA, Rassi A<space/></arg><arg name="title">Challenges and opportunities for primary, secondary, and tertiary prevention of Chagas' disease<space/></arg><arg name="journal">Heart<space/></arg><arg name="volume">95</arg><arg name="issue">7<space/></arg><arg name="pages">524–34<space/></arg><arg name="date">April 2009<space/></arg><arg name="pmid">19131444<space/></arg><arg name="doi">10.1136/hrt.2008.159624</arg><arg name="url">http://heart.bmj.com/cgi/pmidlookup?view</arg></template></extension></preline></preblock><preblock><preline>It is estimated that 7 to 8 million people, mostly in<space/><link><target>Mexico</target></link>,<space/><link><target>Central America</target></link><space/>and<space/><link><target>South America</target></link>, have Chagas disease as of 2013.<extension extension_name='ref' name="WHO2013"><template><target>cite web</target><arg name="title">Chagas disease (American trypanosomiasis) Fact sheet N°340</arg><arg name="url">http://www.who.int/mediacentre/factsheets/fs340/en/</arg><arg name="work">World Health Organization</arg><arg name="accessdate">23 February 2014</arg><arg name="date">March 2013</arg></template></extension><space/>In 2006, Chagas was estimated to result in 12,500 deaths per year.<extension extension_name='ref' name="Rassi2010"></extension><space/>Most people with the disease are poor,<extension extension_name='ref' name="Rassi2010"></extension><space/>and most people with the disease do not realize they are infected.<extension extension_name='ref'><template><target>cite book</target><arg name="editor"><space/>Capinera JL<space/></arg><arg name="title">Encyclopedia of entomology<space/></arg><arg name="year">2008</arg><arg name="publisher">Springer</arg><arg name="location">Dordrecht</arg><arg name="isbn">9781402062421</arg><arg name="page">[https://books.google.com/books?id</arg><arg name="edition">2nd</arg></template></extension><space/>Large-scale population movements have increased the areas where Chagas disease is found and these include many European countries and the United States.<extension extension_name='ref' name="WHO2013"></extension><space/>These areas have also seen an increase in the years up to 2014.<extension extension_name='ref'><template><target>cite journal</target><arg name="author">Bonney KM</arg><arg name="title">Chagas disease in the 21st Century: a public health success or an emerging threat?</arg><arg name="journal">Parasite<space/></arg><arg name="date">2014</arg><arg name="volume">21</arg><arg name="pages">11</arg><arg name="pmid">24626257</arg><arg name="doi">10.1051/parasite/2014012</arg><arg name="pmc">3952655</arg></template><space/><template><target>open access</target></template></extension><space/>The disease was first described in 1909 by<space/><link><target>Carlos Chagas</target></link><space/>after whom it is named.<extension extension_name='ref' name="WHO2013"></extension><space/>It affects more than 150 other animals.<extension extension_name='ref' name="Rassi2010"></extension></preline></preblock><heading level='2'>Signs and symptoms</heading><paragraph><link><target>File:Chagoma.jpg</target><part>thumb</part><part>An acute Chagas disease infection with swelling of the right eye (Romaa's sign).</part></link><link><target>File:Heart pathology Chagas disease.JPG</target><part>thumb</part><part>Large scale anatomy of a heart that has been damaged by chronic Chagas disease&amp;nbsp; see also:<space/><link><target>:Image:Heart radiology Chagas disease.JPG</target><part>Chagas heart, radiology</part></link></part></link>The human disease occurs in two stages: an<space/><link><target>acute (medicine)</target><part>acute</part></link><space/>stage, which occurs shortly after an initial<space/><link><target>infection</target></link>, and a<space/><link><target>chronic (medicine)</target><part>chronic</part></link><space/>stage that develops over many years.</paragraph><paragraph>The acute phase lasts for the first few weeks or months of infection. It usually occurs unnoticed because it is symptom-free or exhibits only mild symptoms that are not unique to Chagas disease. These can include fever, fatigue, body aches, muscle pain, headache, rash, loss of appetite, diarrhea, nausea, and vomiting. The signs on physical examination can include mild enlargement of the liver or spleen, swollen glands, and local swelling (a<space/><link><target>chagoma</target></link>) where the parasite entered the body.<extension extension_name='ref' name="Guimaraes1968"><template><target>cite journal</target><arg name="author">Guimarães FN, da Silva NN, Clausell DT, de Mello AL, Rapone T, Snell T, Rodrigues N</arg><arg name="title">Um surto epidêmico de doença de Chagas de provável transmissão digestiva, ocorrido em Teutonia (Estrêla&nbsp;– Rio Grande Do Sul)<space/></arg><arg name="journal">Hospital (Rio J)<space/></arg><arg name="volume">73<space/></arg><arg name="issue">6<space/></arg><arg name="pages">1767–804</arg><arg name="year">1968<space/></arg><arg name="pmid"><space/>4976999</arg><arg name="language">Portuguese</arg></template></extension></paragraph><paragraph>The most recognized marker of acute Chagas disease is called Romaa's sign, which includes swelling of the eyelids on the side of the face near the bite wound or where the bug feces were deposited or accidentally rubbed into the eye. Rarely, young children, or adults may die from the acute disease due to severe inflammation/infection of the heart muscle (<link><target>myocarditis</target></link>) or brain (<link><target>meningoencephalitis</target></link>).<extension extension_name='ref' name="Guimaraes1968"></extension><space/>The acute phase also can be severe in people with weakened immune systems.<extension extension_name='ref' name="CDC"></extension></paragraph><paragraph>If symptoms develop during the acute phase, they usually resolve spontaneously within three to eight weeks in approximately 90% of individuals.<extension extension_name='ref' name="Rassi2010"></extension><extension extension_name='ref' name="Bern"></extension><space/>Although the symptoms resolve, even with treatment the infection persists and enters a chronic phase. Of individuals with chronic Chagas disease, 6080% will never develop symptoms (called<space/><italics>indeterminate</italics><space/>chronic Chagas disease), while the remaining 2040% will develop life-threatening heart and/or digestive disorders during their lifetime (called<space/><italics>determinate</italics><space/>chronic Chagas disease). In 10% of individuals, the disease progresses directly from the acute form to a symptomatic clinical form of chronic Chagas disease.<extension extension_name='ref' name="Rassi2010"></extension><extension extension_name='ref' name="Bern"></extension></paragraph><paragraph>The symptomatic (determinate) chronic stage affects the<space/><link><target>nervous system</target></link>,<space/><link><target>digestive system</target></link><space/>and<space/><link><target>Human heart</target><part>heart</part></link>. About two-thirds of people with chronic symptoms have cardiac damage, including<space/><link><target>dilated cardiomyopathy</target></link>, which causes heart rhythm abnormalities and may result in sudden death. About one-third of patients go on to develop<space/><link><target>digestive system</target></link><space/>damage, resulting in dilation of the<space/><link><target>digestive tract</target></link><space/>(<link><target>megacolon</target></link><space/>and<space/><link><target>megaesophagus</target></link>), accompanied by severe<space/><link><target>weight loss</target></link>.<space/><link><target>Swallowing</target></link><space/>difficulties (secondary<space/><link><target>achalasia</target></link>) may be the first symptom of digestive disturbances and may lead to<space/><link><target>malnutrition</target></link>.<extension extension_name='ref' name="emed"><template><target>cite web</target><arg name="url">http://emedicine.medscape.com/article/214581-overview<space/></arg><arg name="title">Chagas Disease (American Trypanosomiasis)<space/></arg><arg name="author">Louis V Kirchhoff<space/></arg><arg name="date">17 December 2010</arg><arg name="work"></arg><arg name="publisher">eMedicine<space/></arg><arg name="accessdate">12 May 2010</arg></template></extension></paragraph><paragraph>20% to 50% of individuals with intestinal involvement also exhibit cardiac involvement.<extension extension_name='ref' name="emed"></extension><space/>Up to 10% of chronically infected individuals develop<space/><link><target>neuritis</target></link><space/>that results in altered tendon reflexes and sensory impairment. Isolated cases exhibit central nervous system involvement, including<space/><link><target>dementia</target></link>, confusion, chronic<space/><link><target>encephalopathy</target></link><space/>and<space/><link><target>Stimulus (physiology)</target><part>sensory</part></link><space/>and<space/><link><target>Motor skill</target><part>motor</part></link><space/>deficits.<extension extension_name='ref'><template><target>cite journal</target><arg name="author">Córdova E, Maiolo E, Corti M, Orduña T<space/></arg><arg name="title">Neurological manifestations of Chagas' disease<space/></arg><arg name="journal">Neurol. Res.<space/></arg><arg name="volume">32<space/></arg><arg name="issue">3<space/></arg><arg name="pages">238–44<space/></arg><arg name="date">April 2010<space/></arg><arg name="pmid">20406601<space/></arg><arg name="doi">10.1179/016164110X12644252260637<space/></arg><arg name="url"></arg></template></extension></paragraph><paragraph>The clinical manifestations of Chagas disease are due to cell death in the target tissues that occurs during the infective cycle, by sequentially inducing an<space/><link><target>inflammatory response</target></link>, cellular<space/><link><target>lesions</target></link>, and<space/><link><target>fibrosis</target></link>. For example, intracellular<space/><link><target>amastigote</target><trail>s</trail></link><space/>destroy the intramural neurons of the<space/><link><target>autonomic nervous system</target></link><space/>in the intestine and heart, leading to megaintestine and heart<space/><link><target>aneurysm</target><trail>s</trail></link>, respectively. If left untreated, Chagas disease can be fatal, in most cases due to heart muscle damage.<extension extension_name='ref' name="emed"></extension></paragraph><heading level='2'>Transmission</heading><paragraph><link><target>File:Rhodnius prolixus70-300.jpg</target><part>thumb</part><part>''<link><target>Rhodnius prolixus</target></link>'' is the principal vector in<space/><link><target>Colombia</target></link>,<space/><link><target>Venezuela</target></link>,<space/><link><target>Guatemala</target></link>,<space/><link><target>Honduras</target></link>, and some parts of<space/><link><target>Nicaragua</target></link><space/>and<space/><link><target>El Salvador</target></link>.</part></link></paragraph><paragraph>In Chagas-endemic areas, the main mode of transmission is through an insect<space/><link><target>Vector (epidemiology)</target><part>vector</part></link><space/>called a<space/><link><target>Triatominae</target><part>triatomine</part></link><space/>bug.<extension extension_name='ref' name="CDC"></extension><space/>A triatomine becomes infected with<space/><italics>T. cruzi</italics><space/>by feeding on the blood of an infected person or animal. During the day, triatomines hide in crevices in the walls and roofs.<extension extension_name='ref' name="CDC"></extension></paragraph><paragraph>The bugs emerge at night, when the inhabitants are sleeping. Because they tend to feed on people's faces, triatomine bugs are also known as &quot;kissing bugs&quot;. After they bite and ingest blood, they defecate on the person. Triatomines pass<space/><italics>T. cruzi</italics><space/>parasites (called<space/><link><target>trypomastigote</target><trail>s</trail></link>) in feces left near the site of the bite wound.<extension extension_name='ref' name="CDC"></extension></paragraph><paragraph>Scratching the site of the bite causes the trypomastigotes to enter the host through the wound, or through intact<space/><link><target>mucous membranes</target></link>, such as the<space/><link><target>conjunctiva</target></link>. Once inside the host, the trypomastigotes invade cells, where they differentiate into intracellular<space/><link><target>amastigote</target><trail>s</trail></link>. The amastigotes multiply by<space/><link><target>binary fission</target></link><space/>and differentiate into trypomastigotes, which are then released into the bloodstream. This cycle is repeated in each newly infected cell. Replication resumes only when the parasites enter another cell or are ingested by another vector.<extension extension_name='ref' name="CDC"></extension><space/>(See also:<space/><link><target>:Image:Trypanosoma cruzi LifeCycle.gif</target><part>Life cycle and transmission of ''T. cruzi''</part></link>)</paragraph><paragraph>Dense vegetation (such as that of tropical<space/><link><target>rainforest</target><trail>s</trail></link>) and urban habitats are not ideal for the establishment of the human transmission cycle. However, in regions where the<space/><link><target>sylvatic</target></link><space/><link><target>Habitat (ecology)</target><part>habitat</part></link><space/>and its fauna are thinned by economic exploitation and human habitation, such as in newly<space/><link><target>deforestation</target><part>deforested</part></link><space/>areas,<space/><link><target>piassava palm</target></link><space/>culture areas, and some parts of the<space/><link><target>Amazon River</target><part>Amazon</part></link><space/>region, a human transmission cycle may develop as the insects search for new food sources.<extension extension_name='ref'><template><target>cite journal</target><arg name="author">Teixeira AR, Monteiro PS, Rebelo JM<space/></arg><arg name="title">Emerging Chagas disease: trophic network and cycle of transmission of Trypanosoma cruzi from palm trees in the Amazon<space/></arg><arg name="journal">Emerging Infect Dis<space/></arg><arg name="volume">7<space/></arg><arg name="issue">1<space/></arg><arg name="pages">100–12<space/></arg><arg name="year">2001<space/></arg><arg name="pmid">11266300<space/></arg><arg name="url">http://www.cdc.gov/ncidod/eid/vol7no1/teixeira.htm<space/></arg><arg name="doi">10.3201/eid0701.010115<space/></arg><arg name="pmc">2631687</arg></template></extension></paragraph><paragraph><italics>T. cruzi</italics><space/>can also be transmitted through<space/><link><target>blood transfusions</target></link>. With the exception of blood derivatives (such as fractionated<space/><link><target>antibodies</target></link>), all blood components are infective. The parasite remains viable at 4&amp;nbsp;C for at least 18 days or up to 250 days when kept at room temperature. It is unclear whether<space/><italics>T. cruzi</italics><space/>can be transmitted through frozen-thawed blood components.<extension extension_name='ref'><template><target>cite journal</target><arg name="author">Wendel S<space/></arg><arg name="title">Transfusion transmitted Chagas disease: Is it really under control?<space/></arg><arg name="journal">Acta Trop<space/></arg><arg name="volume"><space/>115</arg><arg name="issue"><space/>1–2</arg><arg name="pages"><space/>28–34</arg><arg name="date">January 2010<space/></arg><arg name="pmid">20044970<space/></arg><arg name="doi">10.1016/j.actatropica.2009.12.006<space/></arg><arg name="url">http://linkinghub.elsevier.com/retrieve/pii/S0001-706X(09)00386-6<space/></arg><arg name="accessdate">13 May 2010</arg></template></extension></paragraph><paragraph>Other modes of transmission include<space/><link><target>organ transplant</target><trail>ation</trail></link>, through<space/><link><target>breast milk</target></link>,<extension extension_name='ref'><template><target>cite journal</target><arg name="author">Santos Ferreira C, Amato Neto V, Gakiya E, Bezerra RC, Alarcón RS<space/></arg><arg name="title">Microwave treatment of human milk to prevent transmission of Chagas disease<space/></arg><arg name="journal">[[Revista do Instituto de Medicina Tropical de São Paulo]]<space/></arg><arg name="volume">45<space/></arg><arg name="issue">1<space/></arg><arg name="pages">41–2<space/></arg><arg name="year">2003<space/></arg><arg name="pmid">12751321<space/></arg><arg name="doi">10.1590/S0036-46652003000100008<space/></arg></template></extension><space/>and by accidental laboratory exposure. Chagas disease can also be spread congenitally (from a pregnant woman to her baby) through the<space/><link><target>placenta</target></link>, and accounts for approximately 13% of stillborn deaths in parts of Brazil.<extension extension_name='ref'><template><target>cite journal</target><arg name="author">Hudson L, Turner MJ<space/></arg><arg name="title">Immunological consequences of infection and vaccination in South American trypanosomiasis [and discussion]<space/></arg><arg name="journal">[[Philosophical Transactions of the Royal Society B]]<space/></arg><arg name="volume">307<space/></arg><arg name="issue">1131<space/></arg><arg name="pages">51–61<space/></arg><arg name="date">November 1984<space/></arg><arg name="pmid">6151688<space/></arg><arg name="jstor">2990154<space/></arg><arg name="doi">10.1098/rstb.1984.0108</arg><arg name="bibcode"><space/>1984RSPTB.307...51H<space/></arg></template><space/>Retrieved 22 February 2007 through<space/><link><target>JSTOR</target></link>.</extension></paragraph><paragraph>Oral transmission is an unusual route of infection, but has been described. In 1991, farm workers in the state of<space/><link><target>Paraba</target></link>, Brazil, were infected by eating contaminated food; transmission has also occurred via contaminated<space/><link><target>aa palm</target></link><space/>fruit juice and<space/><link><target>sugarcane juice</target><part>garapa</part></link>.<extension extension_name='ref'><template><target>cite journal</target><arg name="author">Benchimol-Barbosa PR<space/></arg><arg name="title">The oral transmission of Chagas' disease: an acute form of infection responsible for regional outbreaks.<space/></arg><arg name="journal">Int J Cardiol<space/></arg><arg name="volume">112<space/></arg><arg name="issue">1<space/></arg><arg name="pages">132–3<space/></arg><arg name="year">2006<space/></arg><arg name="pmid">16600406<space/></arg><arg name="doi">10.1016/j.ijcard.2005.11.087<space/></arg></template></extension><extension extension_name='ref'><template><target>cite journal</target><arg name="author">Benchimol-Barbosa PR<space/></arg><arg name="title">Trends on acute Chagas' disease transmitted by oral route in Brazil: steady increase in new cases and a concealed residual fluctuation.<space/></arg><arg name="journal">Int J Cardiol<space/></arg><arg name="volume">145<space/></arg><arg name="issue">3<space/></arg><arg name="pages">494–6<space/></arg><arg name="year">2010<space/></arg><arg name="pmid">19762096<space/></arg><arg name="doi">10.1016/j.ijcard.2009.08.030<space/></arg></template></extension><extension extension_name='ref'><template><target>cite journal</target><arg name="date">April 2005<space/></arg><arg name="title">Chagas' disease (American trypanosomiasis) in southern Brazil<space/></arg><arg name="journal">CDR Weekly<space/></arg><arg name="volume">15<space/></arg><arg name="issue">13<space/></arg><arg name="url">http://www.hpa.org.uk/CDR/archives/2005/cdr1305.pdf<space/></arg><arg name="format">PDF</arg><arg name="publisher">United Kingdom [[Health Protection Agency]]<space/></arg><arg name="accessdate">26 November 2007</arg></template></extension><extension extension_name='ref'><template><target>cite journal</target><arg name="author">Shikanai-Yasuda MA, Marcondes CB, Guedes LA<space/></arg><arg name="title">Possible oral transmission of acute Chagas' disease in Brazil<space/></arg><arg name="journal">Rev Inst Med Trop São Paulo<space/></arg><arg name="volume">33<space/></arg><arg name="issue">5<space/></arg><arg name="pages">351–7<space/></arg><arg name="year">1991<space/></arg><arg name="pmid">1844961<space/></arg><arg name="doi">10.1590/S0036-46651991000500003<space/></arg></template></extension><extension extension_name='ref'><template><target>cite journal</target><arg name="author">da Silva Valente SA, de Costa Valente V, Neto HF<space/></arg><arg name="title">Considerations on the epidemiology and transmission of Chagas disease in the Brazilian Amazon<space/></arg><arg name="journal">Mem Inst Oswaldo Cruz<space/></arg><arg name="volume">94 Suppl 1<space/></arg><arg name="pages">395–8<space/></arg><arg name="year">1999<space/></arg><arg name="pmid">10677763<space/></arg><arg name="url">http://www.scielo.br/scielo.php?script</arg><arg name="doi">10.1590/s0074-02761999000700077</arg></template></extension><space/>A 2007 outbreak in 103 Venezuelan school children was attributed to contaminated<space/><link><target>guava</target></link><space/>juice.<extension extension_name='ref'><template><target>cite journal</target><arg name="vauthors">Alarcón de Noya B, Díaz-Bello Z, Colmenares C, etal<space/></arg><arg name="title">Large urban outbreak of orally acquired acute Chagas disease at a school in Caracas, Venezuela</arg><arg name="journal">J Infect Dis</arg><arg name="year">2010</arg><arg name="volume">201</arg><arg name="issue">9</arg><arg name="pages">1308–15</arg><arg name="pmid">20307205</arg><arg name="doi">10.1086/651608</arg></template></extension></paragraph><paragraph>Chagas disease is a growing problem in Europe, because the majority of cases with chronic infection are asymptomatic and because of migration from Latin America.<extension extension_name='ref' name="Roca2011"><template><target>cite journal</target><arg name="author">Roca C, Pinazo MJ, López-Chejade P, Bayó J, Posada E, López-Solana J, Gállego M, Portús M, Gascón J; Chagas-Clot Research Group</arg><arg name="title">Chagas Disease among the Latin American Adult Population Attending in a Primary Care Center in Barcelona, Spain</arg><arg name="journal">PLoS Negl Trop Dis</arg><arg name="year">2011</arg><arg name="volume">5</arg><arg name="issue">4</arg><arg name="pages">e1135</arg><arg name="pmid">21572511</arg><arg name="doi">10.1371/journal.pntd.0001135</arg><arg name="pmc">3082512</arg><arg name="editor">Da Costa Santiago H</arg></template></extension></paragraph><heading level='2'>Diagnosis</heading><paragraph>The presence of<space/><italics>T. cruzi</italics><space/>is diagnostic of Chagas disease. It can be detected by<space/><link><target>microscope</target><part>microscopic</part></link><space/>examination of fresh anti<link><target>coagulate</target><trail>d</trail></link><space/>blood, or its<space/><link><target>buffy coat</target></link>, for motile parasites; or by preparation of thin and thick blood smears stained with<space/><link><target>Giemsa stain</target><part>Giemsa</part></link>, for direct visualization of<space/><link><target>parasitism</target><part>parasites</part></link>. Microscopically,<space/><italics>T. cruzi</italics><space/>can be confused with<space/><italics><link><target>Trypanosoma rangeli</target></link></italics>, which is not known to be<space/><link><target>pathogen</target><trail>ic</trail></link><space/>in humans. Isolation of<space/><italics>T. cruzi</italics><space/>can occur by inoculation into<space/><link><target>mouse</target><part>mice</part></link>, by culture in specialized media (for example, NNN, LIT); and by<space/><link><target>xenodiagnosis</target></link>,<extension extension_name='ref'><template><target>cite journal</target><arg name="author">Brumpt E</arg><arg name="title">Le xénodiagnostic. Application au diagnostic de quelques infections parasitaires et en particulier à la trypanosomose de Chagas<space/></arg><arg name="journal">Bull Soc Pathol Exot<space/></arg><arg name="volume">7<space/></arg><arg name="issue">10<space/></arg><arg name="pages">706–10</arg><arg name="year">1914<space/></arg><arg name="url">http://www.pathexo.fr/documents/articles-bull/1914/1914n10/T7-10-706.pdf</arg><arg name="format">PDF</arg><arg name="archiveurl">https://web.archive.org/web/20081126053351/http://www.pathexo.fr/documents/articles-bull/1914/1914n10/T7-10-706.pdf</arg><arg name="archivedate">26 November 2008</arg></template></extension><space/>where uninfected<space/><link><target>Reduviidae</target></link><space/>bugs are fed on the patient's blood, and their gut contents examined for parasites.<extension extension_name='ref' name="emed"></extension></paragraph><paragraph>Various<space/><link><target>immunoassay</target><trail>s</trail></link><space/>for<space/><italics>T. cruzi</italics><space/>are available and can be used to distinguish among<space/><link><target>Strain (biology)</target><part>strains</part></link><space/>(zymodemes of<space/><italics>T.cruzi</italics><space/>with divergent pathogenicities). These tests include: detecting<space/><link><target>complement fixation</target></link>, indirect<space/><link><target>hemagglutination</target></link>, indirect<space/><link><target>fluorescence</target></link><space/>assays,<space/><link><target>radioimmunoassay</target><trail>s</trail></link>, and<space/><link><target>ELISA</target></link>. Alternatively, diagnosis and strain identification can be made using<space/><link><target>polymerase chain reaction</target></link><space/>(PCR).<extension extension_name='ref' name="emed"></extension><template><target>Clear</target></template></paragraph><heading level='2'>Prevention</heading><paragraph><link><target>File:Chagas disease. Awareness &amp; prevention campaign poster. French Guiana 2008.JPG</target><part>thumb</part><part>Awareness and prevention campaign poster in<space/><link><target>Cayenne, French Guiana</target></link>, 2008</part></link></paragraph><paragraph>There is currently no vaccine against Chagas disease.<extension extension_name='ref'><template><target>cite web</target><arg name="url">http://www.msf.org/source/actrep/2004/pdf/62-63.pdf<space/></arg><arg name="title"><space/>A killer that preys on the poor: Chagas disease<space/></arg><arg name="format"><space/>pdf<space/></arg><arg name="work">[[Médecins Sans Frontières]]: Activity Report 2003/2004<space/></arg><arg name="accessdate">29 August 2008</arg></template></extension><space/>Prevention is generally focused on decreasing the numbers of the<space/><link><target>Vector (epidemiology)</target><part>insect that spreads it</part></link><space/>(<italics><link><target>Triatoma</target></link></italics>) and decreasing their contact with humans. This is done by using sprays and paints containing<space/><link><target>insecticide</target><trail>s</trail></link><space/>(synthetic<space/><link><target>pyrethroid</target><trail>s</trail></link>), and improving housing and sanitary conditions in rural areas.<extension extension_name='ref'><template><target>cite journal</target><arg name="author">Eduardo N. Zerba</arg><arg name="title">Susceptibility and resistance to insecticides of Chagas disease vectors<space/></arg><arg name="journal">Medicina (Buenos Aires)<space/></arg><arg name="volume">59<space/></arg><arg name="issue">Suppl 2<space/></arg><arg name="pages">41–6<space/></arg><arg name="year">1999<space/></arg><arg name="url">http://www.medicinabuenosaires.com/revistas/vol59-99/supl2/v59_s2_41_46.pdf</arg><arg name="format">PDF</arg></template></extension><space/>For urban dwellers, spending vacations and<space/><link><target>camping</target></link><space/>out in the wilderness or sleeping at hostels or mud houses in endemic areas can be dangerous; a<space/><link><target>mosquito net</target></link><space/>is recommended. Some measures of vector control include:</paragraph><list type='bullet'><listitem>A yeast trap can be used for monitoring infestations of certain species of triatomine bugs (<italics>Triatoma sordida</italics>,<space/><italics>Triatoma brasiliensis</italics>,<space/><italics>Triatoma pseudomaculata</italics>, and<space/><italics>Panstrongylus megistus</italics>).<extension extension_name='ref'><template><target>cite journal</target><arg name="author">Pires HH, Lazzari CR, Diotaiuti L, Lorenzo MG<space/></arg><arg name="title">Performance of yeast-baited traps with ''Triatoma sordida'', ''Triatoma brasiliensis'', ''Triatoma pseudomaculata'', and ''Panstrongylus megistus'' in laboratory assays<space/></arg><arg name="journal">Rev Panam Salud Publica<space/></arg><arg name="volume">7<space/></arg><arg name="issue">6<space/></arg><arg name="pages">384–8<space/></arg><arg name="date">June 2000<space/></arg><arg name="pmid">10949899<space/></arg><arg name="doi">10.1590/S1020-49892000000600005</arg></template></extension></listitem><listitem>Promising results were gained with the treatment of vector habitats with the fungus<space/><italics><link><target>Beauveria bassiana</target></link></italics>.<extension extension_name='ref'><template><target>cite journal</target><arg name="author">Luz C, Rocha LF, Nery GV, Magalhães BP, Tigano MS<space/></arg><arg name="title">Activity of oil-formulated ''Beauveria bassiana'' against ''Triatoma sordida'' in peridomestic areas in Central Brazil<space/></arg><arg name="journal">Mem Inst Oswaldo Cruz<space/></arg><arg name="volume">99<space/></arg><arg name="issue">2<space/></arg><arg name="pages">211–8<space/></arg><arg name="date">March 2004<space/></arg><arg name="pmid">15250478<space/></arg><arg name="doi">10.1590/S0074-02762004000200017<space/></arg><arg name="url">http://www.scielo.br/scielo.php?script</arg></template></extension></listitem><listitem>Targeting the<space/><link><target>symbiont</target><trail>s</trail></link><space/>of<space/><link><target>Triatominae</target></link><space/>through<space/><link><target>paratransgenesis</target></link><space/>can be done.<extension extension_name='ref' name="pmid11729071"><template><target>cite journal</target><arg name="author">Beard CB, Cordon-Rosales C, Durvasula RV<space/></arg><arg name="title">Bacterial symbionts of the Triatominae and their potential use in control of Chagas disease transmission<space/></arg><arg name="journal">Annu Rev Entomol<space/></arg><arg name="volume">47<space/></arg><arg name="pages">123–41<space/></arg><arg name="year">2002<space/></arg><arg name="pmid">11729071<space/></arg><arg name="doi">10.1146/annurev.ento.47.091201.145144<space/></arg><arg name="url">http://arjournals.annualreviews.org/doi/abs/10.1146/annurev.ento.47.091201.145144?url_ver</arg></template></extension></listitem></list><paragraph>A number of potential vaccines are currently being tested. Vaccination with<space/><italics><link><target>Trypanosoma rangeli</target></link></italics><space/>has produced positive results in animal models.<extension extension_name='ref' name="pmid18660992"><template><target>cite journal</target><arg name="author">Basso B, Moretti E, Fretes R<space/></arg><arg name="title">Vaccination with epimastigotes of different strains of''Trypanosoma rangeli'' protects mice against ''Trypanosoma cruzi'' infection<space/></arg><arg name="journal">Mem Inst Oswaldo Cruz<space/></arg><arg name="volume">103<space/></arg><arg name="issue">4<space/></arg><arg name="pages">370–4<space/></arg><arg name="date">June 2008<space/></arg><arg name="pmid">18660992<space/></arg><arg name="doi"><space/>10.1590/S0074-02762008000400010</arg><arg name="url">http://www.scielo.br/scielo.php?script</arg></template></extension><space/>More recently, the potential of DNA vaccines for<space/><link><target>immunotherapy</target></link><space/>of acute and chronic Chagas disease is being tested by several research groups.<extension extension_name='ref'><template><target>cite journal</target><arg name="author">Dumonteil E, Escobedo-Ortegon J, Reyes-Rodriguez N, Arjona-Torres A, Ramirez-Sierra M<space/></arg><arg name="title">Immunotherapy of ''Trypanosoma cruzi'' Infection with DNA Vaccines in Mice<space/></arg><arg name="journal">Infect Immun<space/></arg><arg name="volume">72<space/></arg><arg name="issue">1<space/></arg><arg name="pages">46–53<space/></arg><arg name="year">2004<space/></arg><arg name="pmid">14688079<space/></arg><arg name="doi"><space/>10.1128/IAI.72.1.46-53.2004<space/></arg><arg name="pmc">343959</arg></template></extension></paragraph><paragraph><link><target>Blood transfusion</target></link><space/>was formerly the second-most common mode of transmission for Chagas disease, but the development and implementation of<space/><link><target>blood bank</target></link><space/>screening tests has dramatically reduced this risk in the 21st century.<space/><link><target>Blood donation</target><trail>s</trail></link><space/>in all endemic Latin American countries undergo Chagas screening, and testing is expanding in countries, such as France, Spain and the United States, that have significant or growing populations of immigrants from endemic areas.<extension extension_name='ref'><template><target>cite journal</target><arg name="author">Castro E<space/></arg><arg name="title">Chagas' disease: lessons from routine donation testing<space/></arg><arg name="journal">Transfus Med<space/></arg><arg name="volume">19<space/></arg><arg name="issue">1<space/></arg><arg name="pages">16–23<space/></arg><arg name="date">February 2009<space/></arg><arg name="pmid">19302451<space/></arg><arg name="doi">10.1111/j.1365-3148.2009.00915.x<space/></arg><arg name="url">http://www3.interscience.wiley.com/resolve/openurl?genre</arg><arg name="accessdate">12 May 2010</arg></template></extension><extension extension_name='ref' name="Gascon"><template><target>cite journal</target><arg name="author">Gascon J, Bern C, Pinazo MJ<space/></arg><arg name="title">Chagas disease in Spain, the United States and other non-endemic countries<space/></arg><arg name="journal">Acta Trop.<space/></arg><arg name="volume"><space/>115</arg><arg name="issue"><space/>1–2</arg><arg name="pages"><space/>22–7</arg><arg name="date">July 2009<space/></arg><arg name="pmid">19646412<space/></arg><arg name="doi">10.1016/j.actatropica.2009.07.019<space/></arg><arg name="url">http://linkinghub.elsevier.com/retrieve/pii/S0001-706X(09)00199-5</arg><arg name="accessdate">12 May 2010</arg></template></extension><space/>In Spain, donors are evaluated with a questionnaire to identify individuals at risk of Chagas exposure for screening tests.<extension extension_name='ref' name="Gascon"></extension></paragraph><paragraph>The US FDA has approved two Chagas tests, including one approved in April 2010, and has published guidelines that recommend testing of all donated blood and tissue products.<extension extension_name='ref' name="Gascon"></extension><extension extension_name='ref' name="FDA"><template><target>cite web</target><arg name="url">http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm210429.htm<space/></arg><arg name="title">FDA Approves Chagas Disease Screening Test for Blood, Tissue and Organ Donors<space/></arg><arg name="accessdate">12 May 2010</arg></template></extension><space/>While these tests are not required in US, an estimated 7590% of the blood supply is currently tested for Chagas, including all units collected by the<space/><link><target>American Red Cross</target></link>, which accounts for 40% of the U.S. blood supply.<extension extension_name='ref' name="FDA"></extension><extension extension_name='ref'><template><target>cite web</target><arg name="url">http://www.redcrossblood.org/hospitals/infectious-disease-testing#Chagas__disease__T._cruzi___2007_<space/></arg><arg name="title">Infectious Disease Testing<space/></arg><arg name="work">American Red Cross</arg><arg name="accessdate">12 May 2010</arg></template></extension><space/>The Chagas Biovigilance Network reports current incidents of Chagas-positive blood products in the United States, as reported by labs using the screening test approved by the FDA in 2007.<extension extension_name='ref'><template><target>cite web</target><arg name="url">http://www.aabb.org/programs/biovigilance/Pages/chagas.aspx<space/></arg><arg name="title">Chagas' Biovigilance Network<space/></arg><arg name="work"></arg><arg name="accessdate">12 May 2010</arg></template></extension></paragraph><heading level='2'>Management</heading><paragraph>There are two approaches to treating Chagas disease:<space/><link><target>antiparasitic</target></link><space/>treatment, to kill the parasite; and symptomatic treatment, to manage the symptoms and signs of the infection. Management uniquely involves addressing selective incremental failure of the parasympathetic nervous system. Autonomic disease imparted by Chagas may eventually result in megaesophagus, megacolon and accelerated dilated cardiomyopathy. The mechanisms that explain why Chagas targets the parasympathetic autonomic nervous system and spares the sympathetic autonomic nervous system remain poorly understood.</paragraph><heading level='3'>Medication</heading><paragraph>Antiparasitic treatment is most effective early in the course of infection, but is not limited to cases in the acute phase. Drugs of choice include<space/><link><target>azole</target></link><space/>or<space/><link><target>Nitro compound</target><part>nitro</part></link><space/>derivatives, such as<space/><link><target>benznidazole</target></link><extension extension_name='ref'><template><target>cite journal</target><arg name="author">Garcia S, Ramos CO, Senra JF<space/></arg><arg name="title">Treatment with Benznidazole during the Chronic Phase of Experimental Chagas' Disease Decreases Cardiac Alterations<space/></arg><arg name="journal">[[Antimicrobial Agents and Chemotherapy|Antimicrob Agents Chemother]]<space/></arg><arg name="volume">49<space/></arg><arg name="issue">4<space/></arg><arg name="pages">1521–8<space/></arg><arg name="date">April 2005<space/></arg><arg name="pmid">15793134<space/></arg><arg name="pmc">1068607<space/></arg><arg name="doi">10.1128/AAC.49.4.1521-1528.2005<space/></arg><arg name="url">http://aac.asm.org/cgi/pmidlookup?view</arg></template></extension><space/>or<space/><link><target>nifurtimox</target></link>. Both agents are limited in their capacity to completely eliminate<space/><italics>T. cruzi</italics><space/>from the body (parasitologic cure), especially in chronically infected patients, and resistance to these drugs has been reported.<extension extension_name='ref'><template><target>cite journal</target><arg name="author">Buckner FS, Wilson AJ, White TC, Van Voorhis WC<space/></arg><arg name="title">Induction of Resistance to Azole Drugs in ''Trypanosoma cruzi''<space/></arg><arg name="journal">Antimicrob Agents Chemother<space/></arg><arg name="volume">42<space/></arg><arg name="issue">12<space/></arg><arg name="pages">3245–50<space/></arg><arg name="date">December 1998<space/></arg><arg name="pmid">9835521<space/></arg><arg name="pmc">106029<space/></arg><arg name="url">http://aac.asm.org/cgi/pmidlookup?view</arg></template></extension></paragraph><paragraph>Studies suggest antiparasitic treatment leads to parasitological cure in more than 90% of infants but only about 6085% of adults treated in the first year of acute phase Chagas disease. Children aged six to 12 years with chronic disease have a cure rate of about 60% with benznidazole. While the rate of cure declines the longer an adult has been infected with Chagas, treatment with benznidazole has been shown to slow the onset of heart disease in adults with chronic Chagas infections.<extension extension_name='ref' name="Rassi2010"></extension><extension extension_name='ref' name="emed"></extension></paragraph><paragraph>Treatment of chronic infection in women prior to or during pregnancy does not appear to reduce the probability the disease will be passed on to the infant. Likewise, it is unclear whether<space/><link><target>prophylactic</target></link><space/>treatment of chronic infection is beneficial in persons who will undergo immunosuppression (for example, organ transplant recipients) or in persons who are already immunosuppressed (for example, those with HIV infection).<extension extension_name='ref' name="emed"></extension></paragraph><heading level='3'>Complications</heading><paragraph>In the chronic stage, treatment involves managing the clinical manifestations of the disease. For example,<space/><link><target>pacemaker</target><trail>s</trail></link><space/>and medications for irregular heartbeats, such as the anti-arrhythmia drug<space/><link><target>amiodarone</target></link>, may be life saving for some patients with chronic cardiac disease,<extension extension_name='ref'><template><target>cite journal</target><arg name="author">Dubner S, Schapachnik E, Riera AR, Valero E<space/></arg><arg name="title">Chagas disease: state-of-the-art of diagnosis and management<space/></arg><arg name="journal">Cardiol J<space/></arg><arg name="volume">15<space/></arg><arg name="issue">6<space/></arg><arg name="pages">493–504<space/></arg><arg name="year">2008<space/></arg><arg name="pmid">19039752</arg></template></extension><space/>while surgery may be required for megaintestine. The disease cannot be cured in this phase, however. Chronic heart disease caused by Chagas disease is now a common reason for<space/><link><target>heart transplantation</target></link><space/>surgery. Until recently, however, Chagas disease was considered a<space/><link><target>contraindication</target></link><space/>for the procedure, since the heart damage could recur as the parasite was expected to seize the opportunity provided by the<space/><link><target>immunosuppression</target></link><space/>that follows surgery.<extension extension_name='ref'><template><target>cite journal</target><arg name="author">Bocchi EA, Bellotti G, Mocelin AO<space/></arg><arg name="title">Heart transplantation for chronic Chagas' heart disease<space/></arg><arg name="journal">Ann Thorac Surg<space/></arg><arg name="volume">61<space/></arg><arg name="issue">6<space/></arg><arg name="pages">1727–33<space/></arg><arg name="date">June 1996<space/></arg><arg name="pmid">8651775<space/></arg><arg name="doi">10.1016/0003-4975(96)00141-5<space/></arg><arg name="url">http://linkinghub.elsevier.com/retrieve/pii/0003-4975(96)00141-5</arg></template></extension></paragraph><heading level='2'>Epidemiology</heading><paragraph><link><target>File:Distribution of Chagas' disease.svg</target><part>thumb</part><part>350px</part><part>Chagas disease in Latin America (<link><target>Endemic (epidemiology)</target><part>endemic</part></link><space/>zones).</part></link>Chagas disease affects 8 to 10&amp;nbsp;million people living in endemic Latin American countries, with an additional 300,000400,000 living in nonendemic countries, including Spain and the United States. An estimated 41,200 new cases occur annually in endemic countries, and 14,400 infants are born with congenital Chagas disease annually.<extension extension_name='ref' name="Rassi2010"></extension><extension extension_name='ref' name="emed"></extension><space/>in 2010 it resulted in approximately 10,300 deaths up from 9,300 in 1990.<extension extension_name='ref' name="Loz2012"><template><target>cite journal</target><arg name="author">Lozano R</arg><arg name="title">Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010</arg><arg name="journal">Lancet</arg><arg name="date">15 December 2012</arg><arg name="volume">380</arg><arg name="issue">9859</arg><arg name="pages">2095–128</arg><arg name="pmid">23245604</arg><arg name="doi">10.1016/S0140-6736(12)61728-0</arg></template></extension></paragraph><paragraph>The disease is present in 18 countries on the American continents, ranging from the southern United States to northern<space/><link><target>Argentina</target></link>.<extension extension_name='ref' name="CDC"></extension><space/>Chagas exists in two different ecological zones. In the<space/><link><target>Southern Cone</target></link><space/>region, the main vector lives in and around human homes. In Central America and Mexico, the main vector species lives both inside dwellings and in uninhabited areas. In both zones, Chagas occurs almost exclusively in rural areas, where triatomines breed and feed on the more than 150 species from 24 families of domestic and wild mammals, as well as humans, that are the<space/><link><target>natural reservoir</target><trail>s</trail></link><space/>of<space/><italics>T. cruzi</italics>.<extension extension_name='ref' name="NatRev"><template><target>cite journal</target><arg name="author">Morel CM, Lazdins J<space/></arg><arg name="title">Chagas disease<space/></arg><arg name="journal">Nat Rev Microbiol<space/></arg><arg name="volume">1<space/></arg><arg name="issue">1<space/></arg><arg name="pages">14–5<space/></arg><arg name="date">October 2003<space/></arg><arg name="pmid">15040175<space/></arg><arg name="doi">10.1038/nrmicro735</arg></template></extension></paragraph><paragraph>Although Triatominae bugs feed on them, birds appear to be immune to infection and therefore are not considered to be a<space/><italics>T. cruzi</italics><space/>reservoir. Even when colonies of insects are eradicated from a house and surrounding domestic animal shelters, they can re-emerge from plants or animals that are part of the ancient,<space/><link><target>sylvatic</target></link><space/>(referring to wild animals) infection cycle. This is especially likely in zones with mixed open savannah, with clumps of trees interspersed by human habitation.<extension extension_name='ref'><template><target>cite conference</target><arg name="author">Pinto-Dias JC<space/></arg><arg name="year"><space/>1992<space/></arg><arg name="title"><space/>Epidemiology of Chagas disease<space/></arg><arg name="conference"><space/>ISBT Brazil '92. XXII Congress of the International Society of Blood Transfusion. XX Brazilian Congress of Hematology. Extraordinary Congress of the Brazilian College of Hematology<space/></arg><arg name="booktitle"><space/>Chagas Disease&nbsp;– American Trypanosomiasis: its impact on transfusion and clinical medicine<space/></arg><arg name="editor"><space/>Wendel S, Brener Z, Camargo ME, Rassi A (eds.)<space/></arg><arg name="publisher">Editorial ISBT Brazil<space/></arg><arg name="location"><space/>São Paulo<space/></arg><arg name="url"><space/>http://www.dbbm.fiocruz.br/tropical/chagas/chapter4.html<space/></arg><arg name="accessdate">11 September 2008<space/></arg><arg name="oclc">69892472</arg></template></extension></paragraph><paragraph>The primary wildlife reservoirs for<space/><italics>Trypanosoma cruzi</italics><space/>in the United States include<space/><link><target>opossum</target><trail>s</trail></link>,<space/><link><target>raccoon</target><trail>s</trail></link>,<space/><link><target>armadillo</target><trail>s</trail></link>,<space/><link><target>squirrel</target><trail>s</trail></link>,<space/><link><target>woodrat</target><trail>s</trail></link>, and<space/><link><target>mice</target></link>.<extension extension_name='ref' name="Karsten92"></extension><space/>Opossums are particularly important as reservoirs, because the parasite can complete its life cycle in the anal glands of this animal without having to re-enter the insect vector.<extension extension_name='ref' name="Karsten92"><template><target>cite journal</target><arg name="author">Karsten V, Davis C, Kuhn R<space/></arg><arg name="title">''Trypanosoma cruzi'' in wild raccoons and opossums in North Carolina<space/></arg><arg name="journal">J Parasitol<space/></arg><arg name="volume">78<space/></arg><arg name="issue">3<space/></arg><arg name="pages">547–9<space/></arg><arg name="date">June 1992<space/></arg><arg name="pmid">1597808<space/></arg><arg name="doi">10.2307/3283667<space/></arg><arg name="jstor">3283667</arg></template></extension><space/>Recorded prevalence of the disease in opossums in the U.S. ranges from 8.3%<extension extension_name='ref' name="Karsten92"></extension><space/>to 37.5%.<extension extension_name='ref' name="Barr91"><template><target>cite journal</target><arg name="author">Barr SC, Brown CC, Dennis VA, Klei TR<space/></arg><arg name="title">The lesions and prevalence of ''Trypanosoma cruzi'' in opossums and armadillos from southern Louisiana<space/></arg><arg name="journal">J Parasitol<space/></arg><arg name="volume">77<space/></arg><arg name="issue">4<space/></arg><arg name="pages">624–7<space/></arg><arg name="date">August 1991<space/></arg><arg name="pmid">1907654<space/></arg><arg name="doi">10.2307/3283170<space/></arg><arg name="jstor">3283170</arg></template></extension></paragraph><paragraph>Studies on raccoons in the Southeast have yielded infection rates ranging from 47%<extension extension_name='ref'><template><target>cite journal</target><arg name="author">Yabsley MJ, Noblet GP<space/></arg><arg name="title">Seroprevalence of ''Trypanosoma cruzi'' in raccoons from South Carolina and Georgia<space/></arg><arg name="journal">J Wildl Dis<space/></arg><arg name="volume">38<space/></arg><arg name="issue">1<space/></arg><arg name="pages">75–83<space/></arg><arg name="date">1 January 2002</arg><arg name="pmid">11838232<space/></arg><arg name="url">http://www.jwildlifedis.org/cgi/pmidlookup?view</arg><arg name="doi">10.7589/0090-3558-38.1.75</arg></template></extension><space/>to as low as 15.5%.<extension extension_name='ref' name="Karsten92"></extension><space/>Armadillo prevalence studies have been described in Louisiana, and range from a low of 1.1%<extension extension_name='ref' name="Barr91"></extension><space/>to 28.8%.<extension extension_name='ref'><template><target>cite journal</target><arg name="author">Yaeger RG<space/></arg><arg name="title">The prevalence of ''Trypanosoma cruzi'' infection in armadillos collected at a site near New Orleans, Louisiana<space/></arg><arg name="journal">Am J Trop Med Hyg<space/></arg><arg name="volume">38<space/></arg><arg name="issue">2<space/></arg><arg name="pages">323–6<space/></arg><arg name="date">March 1988<space/></arg><arg name="pmid">3128127<space/></arg><arg name="url">http://www.ajtmh.org/cgi/pmidlookup?view</arg></template></extension><space/>Additionally, small rodents, including squirrels, mice, and rats, are important in the sylvatic transmission cycle because of their importance as bloodmeal sources for the insect vectors. A Texas study revealed 17.3% percent<space/><italics>T. cruzi</italics><space/>prevalence in 75 specimens representing four separate small rodent species.<extension extension_name='ref'><template><target>cite journal</target><arg name="author">Burkholder JE, Allison TC, Kelly VP<space/></arg><arg name="title">''Trypanosoma cruzi'' (Chagas) (Protozoa: Kinetoplastida) in invertebrate, reservoir, and human hosts of the lower Rio Grande valley of Texas<space/></arg><arg name="journal">J Parasitol<space/></arg><arg name="volume">66<space/></arg><arg name="issue">2<space/></arg><arg name="pages">305–11<space/></arg><arg name="date">April 1980<space/></arg><arg name="pmid">6771371<space/></arg><arg name="doi">10.2307/3280824<space/></arg><arg name="jstor">3280824</arg></template></extension></paragraph><paragraph>Chronic Chagas disease remains a major health problem in many Latin American countries, despite the effectiveness of hygienic and preventive measures, such as eliminating the transmitting insects. However, several landmarks have been achieved in the fight against it in Latin America, including a reduction by 72% of the incidence of human infection in children and young adults in the countries of the<space/><link><target>Southern Cone</target></link><space/>Initiative, and at least three countries (<link><target>Uruguay</target></link>, in 1997, and<space/><link><target>Chile</target></link>, in 1999, and Brazil in 2006) have been certified free of vectorial and transfusional transmission.<extension extension_name='ref' name="emed"></extension><extension extension_name='ref' name="TDR1"><template><target>cite press release</target><arg name="url">http://www.who.int/tdrold/publications/tdrnews/news65/chagas.htm<space/></arg><arg name="title">The Southern Cone Initiative: an update<space/></arg><arg name="work">Special Programme for Research and Training in Tropical Diseases (TDR)<space/></arg><arg name="publisher">WHO<space/></arg><arg name="year">2004<space/></arg><arg name="accessdate">29 August 2008<space/></arg><arg name="deadurl">yes<space/></arg><arg name="archiveurl">https://web.archive.org/20090922232932/http://www.who.int:80/tdrold/publications/tdrnews/news65/chagas.htm<space/></arg><arg name="archivedate">22 September 2009<space/></arg></template></extension><extension extension_name='ref' name="pmid18053273"><template><target>cite journal</target><arg name="author">Massad E<space/></arg><arg name="title">The elimination of Chagas' disease from Brazil<space/></arg><arg name="journal">Epidemiol Infect<space/></arg><arg name="volume">136<space/></arg><arg name="issue">9<space/></arg><arg name="pages">1153–64<space/></arg><arg name="date">September 2008<space/></arg><arg name="pmid">18053273<space/></arg><arg name="doi">10.1017/S0950268807009879<space/></arg><arg name="url">http://journals.cambridge.org/abstract_S0950268807009879<space/></arg><arg name="pmc">2870925</arg></template></extension><space/>In Argentina, vectorial transmission has been interrupted in 13 of the 19 endemic provinces,<extension extension_name='ref' name="TDR1"></extension><space/>and major progress toward this goal has also been made in both Paraguay and Bolivia.</paragraph><paragraph>Screening of donated blood, blood components, and solid organ donors, as well as donors of cells, tissues, and cell and tissue products for<space/><italics>T. cruzi</italics><space/>is mandated in all Chagas-endemic countries and has been implemented.<extension extension_name='ref'><template><target>cite journal</target><arg name="author">Castro E<space/></arg><arg name="title">Chagas' disease: lessons from routine donation testing<space/></arg><arg name="journal">Transfus Med<space/></arg><arg name="volume">19<space/></arg><arg name="issue">1<space/></arg><arg name="pages">16–23<space/></arg><arg name="date">February 2009<space/></arg><arg name="pmid">19302451<space/></arg><arg name="doi">10.1111/j.1365-3148.2009.00915.x<space/></arg><arg name="url">http://www3.interscience.wiley.com/resolve/openurl?genre</arg><arg name="accessdate">13 May 2010</arg></template></extension><space/>Approximately 300,000 infected people live in the United States, which is likely the result of immigration from Latin American countries.<extension extension_name='ref'><template><target>cite web</target><arg name="publisher">National Institutes of Health<space/></arg><arg name="url"><space/>http://www.nlm.nih.gov/medlineplus/ency/article/001372.htm<space/></arg><arg name="title">Medical Encyclopedia: Chagas disease<space/></arg><arg name="accessdate">11 September 2008</arg></template></extension><space/>With increased population movements, the possibility of transmission by blood transfusion became more substantial in the United States. Transfusion blood and tissue products are now actively screened in the U.S., thus addressing and minimizing this risk.<extension extension_name='ref'><template><target>cite journal</target><arg name="author">Kirchhoff LV<space/></arg><arg name="title">American trypanosomiasis (Chagas' disease)&nbsp;– a tropical disease now in the United States<space/></arg><arg name="journal">N Engl J Med<space/></arg><arg name="volume">329<space/></arg><arg name="issue">9<space/></arg><arg name="pages">639–44<space/></arg><arg name="date">August 1993<space/></arg><arg name="pmid">8341339<space/></arg><arg name="doi"><space/>10.1056/NEJM199308263290909</arg></template></extension></paragraph><heading level='2'>History</heading><paragraph><link><target>File:Carlos chagas 2.jpg</target><part>thumb</part><part><link><target>Carlos Chagas</target></link>, in his laboratory at the<space/><link><target>Oswaldo Cruz Foundation</target><part>Instituto Oswaldo Cruz</part></link>.</part></link></paragraph><paragraph>The disease was named after the<space/><link><target>Brazil</target><trail>ian</trail></link><space/>physician and<space/><link><target>Epidemiology</target><part>epidemiologist</part></link><space/><link><target>Carlos Chagas</target></link>, who first described it in 1909.<extension extension_name='ref' name="Chagas_1909"><template><target>cite journal</target><arg name="author">Chagas C<space/></arg><arg name="title">Neue Trypanosomen<space/></arg><arg name="journal">Vorläufige Mitteilung Arch Schiff Tropenhyg<space/></arg><arg name="year">1909<space/></arg><arg name="volume">13<space/></arg><arg name="pages"><space/>120–2<space/></arg></template></extension><extension extension_name='ref' name="Redhead_2006"><template><target>cite journal</target><arg name="author">Redhead SA, Cushion MT, Frenkel JK, Stringer JR<space/></arg><arg name="title">''Pneumocystis'' and ''Trypanosoma cruzi'': nomenclature and typifications<space/></arg><arg name="journal">J Eukaryot Microbiol<space/></arg><arg name="year">2006<space/></arg><arg name="pages">2–11<space/></arg><arg name="volume">53<space/></arg><arg name="issue">1<space/></arg><arg name="pmid">16441572<space/></arg><arg name="doi">10.1111/j.1550-7408.2005.00072.x</arg></template></extension><extension extension_name='ref' name="Chagas_1909b"><template><target>cite journal</target><arg name="author">Chagas C<space/></arg><arg name="title">Nova tripanozomiase humana: Estudos sobre a morfolojia e o ciclo evolutivo do Schizotrypanum cruzi n. gen., n. sp., ajente etiolojico de nova entidade morbida do homem [New human trypanosomiasis. Studies about the morphology and life-cycle of ''Schizotripanum cruzi'', etiological agent of a new morbid entity of man]<space/></arg><arg name="journal">Mem Inst Oswaldo Cruz<space/></arg><arg name="year">1909<space/></arg><arg name="volume">1<space/></arg><arg name="issue">2<space/></arg><arg name="pages">159–218<space/></arg><arg name="issn">0074-0276<space/></arg><arg name="doi">10.1590/S0074-02761909000200008<space/></arg></template><space/>(in Portuguese with German full translation as &quot;Ueber eine neue Trypanosomiasis des Menschen.&quot;)</extension><extension extension_name='ref'><template><target>cite journal</target><arg name="journal">Hist Cienc Saude Manguinhos<space/></arg><arg name="date">July 2009<space/></arg><arg name="volume">16<space/></arg><arg name="issue">Suppl 1<space/></arg><arg name="pages">13–34<space/></arg><arg name="title">The discovery of ''Trypanosoma cruzi'' and Chagas disease (1908–1909): tropical medicine in Brazil<space/></arg><arg name="author">Kropf SP, Sá MR<space/></arg><arg name="pmid">20027916<space/></arg><arg name="doi">10.1590/s0104-59702009000500002</arg></template></extension><space/>The disease was not seen as a major<space/><link><target>public health</target></link><space/>problem in humans until the 1960s (the outbreak of Chagas disease in Brazil in the 1920s went widely ignored<extension extension_name='ref'><template><target>cite journal</target><arg name="author">Coutinho M<space/></arg><arg name="title">Review of ''Historical Aspects of American Trypanosomiasis (Chagas' Disease)'' by Matthias Perleth<space/></arg><arg name="journal">Isis<space/></arg><arg name="volume">90<space/></arg><arg name="issue">2<space/></arg><arg name="date">June 1999<space/></arg><arg name="pages">397<space/></arg><arg name="doi">10.1086/384393<space/></arg><arg name="jstor">237120</arg></template></extension>). Dr Chagas discovered that the intestines of Triatomidae (now<space/><link><target>Reduviidae</target></link>:<space/><link><target>Triatominae</target></link>) harbored a<space/><link><target>flagellate</target></link><space/>protozoan, a new species of the<space/><italics><link><target>Trypanosoma</target></link></italics><space/>genus, and was able to prove experimentally that it could be transmitted to<space/><link><target>marmoset</target></link><space/>monkeys that were bitten by the infected bug. Later studies showed<space/><link><target>squirrel monkey</target><trail>s</trail></link><space/>were also vulnerable to infection.<extension extension_name='ref' name="Hulsebos_1989"><template><target>cite journal</target><arg name="author">Hulsebos LH, Choromanski L, Kuhn RE<space/></arg><arg name="title">The effect of interleukin-2 on parasitemia and myocarditis in experimental Chagas' disease<space/></arg><arg name="journal">J Protozool<space/></arg><arg name="volume">36<space/></arg><arg name="issue">3<space/></arg><arg name="pages">293–8<space/></arg><arg name="year">1989<space/></arg><arg name="pmid">2499678<space/></arg><arg name="doi">10.1111/j.1550-7408.1989.tb05366.x</arg></template></extension></paragraph><paragraph>Chagas named the pathogenic parasite as<space/><italics>Trypanosoma cruzi</italics><extension extension_name='ref' name="Chagas_1909"></extension><space/>and later that year as<space/><italics>Schizotrypanum cruzi</italics>,<extension extension_name='ref' name="Chagas_1909b"></extension><space/>both honoring<space/><link><target>Oswaldo Cruz</target></link>, the noted Brazilian physician and<space/><link><target>epidemiologist</target></link><space/>who successfully fought epidemics of<space/><link><target>yellow fever</target></link>,<space/><link><target>smallpox</target></link>, and<space/><link><target>bubonic plague</target></link><space/>in<space/><link><target>Rio de Janeiro</target></link><space/>and other cities in the beginning of the 20th century. Chagas was also the first to unknowingly discover and illustrate the parasitic fungal genus<space/><italics><link><target>Pneumocystis pneumonia</target><part>Pneumocystis</part></link></italics>, later infamously linked to PCP (<italics>Pneumocystis</italics><space/><link><target>pneumonia</target></link><space/>in AIDS victims).<extension extension_name='ref' name="Redhead_2006"></extension><space/>Confusion between the two pathogens' life-cycles led him to briefly recognize his genus<space/><italics>Schizotrypanum</italics>, but following the description of<space/><italics>Pneumocystis</italics><space/>by others as an independent genus, Chagas returned to the use of the name<space/><italics>Trypanosoma cruzi</italics>.</paragraph><paragraph>In<space/><link><target>Argentina</target></link>, the disease is known as<space/><italics>mal de Chagas-Mazza</italics>, in honor of<space/><link><target>Salvador Mazza</target></link>, the<space/><link><target>Argentina</target><part>Argentine</part></link><space/>physician who in 1926 began investigating the disease and over the years became the principal researcher of this disease in the country.<extension extension_name='ref'><template><target>cite web</target><arg name="url">http://www.drwebsa.com.ar/alcha/hist4.htm<space/></arg><arg name="publisher">Asociación Lucha Contra el Mal de Chagas<space/></arg><arg name="title">Enfermedad de Chagas&nbsp;– Mazza<space/></arg><arg name="language">Spanish<space/></arg><arg name="accessdate">15 September 2011</arg></template></extension><space/>Mazza produced the first scientific confirmation of the existence of<space/><italics><link><target>Trypanosoma cruzi</target></link></italics><space/>in Argentina in 1927, eventually leading to support from local and European medical schools and Argentine government policy makers.<extension extension_name='ref'><template><target>cite web</target><arg name="url">http://www.fac.org.ar/fec/chagas/fatala/historia.htm<space/></arg><arg name="title">Historia de la enfermedad de Chagas<space/></arg><arg name="language">Spanish</arg><arg name="archiveurl">https://web.archive.org/web/20091204113113/http://www.fac.org.ar/fec/chagas/fatala/historia.htm<space/></arg><arg name="archivedate">4 December 2009<space/></arg></template></extension></paragraph><paragraph>It has been hypothesized that<space/><link><target>Charles Darwin</target></link><space/>might have suffered from Chagas disease as a result of a bite of the so-called great black bug of the<space/><link><target>Pampas</target></link><space/>(<italics>vinchuca</italics>) (see<space/><link><target>Charles Darwin's illness</target></link>). The episode was reported by Darwin in his diaries of<space/><link><target>the Voyage of the Beagle</target></link><space/>as occurring in March 1835 to the east of the<space/><link><target>Andes</target></link><space/>near<space/><link><target>Mendoza Province</target><part>Mendoza</part></link>. Darwin was young and generally in good health, though six months previously he had been ill for a month near<space/><link><target>Valparaiso</target></link>, but in 1837, almost a year after he returned to England, he began to suffer intermittently from a strange group of<space/><link><target>symptom</target><trail>s</trail></link>, becoming incapacitated for much of the rest of his life. Attempts to test Darwin's remains at<space/><link><target>Westminster Abbey</target></link><space/>by using modern<space/><link><target>PCR</target></link><space/>techniques were met with a refusal by the Abbey's<space/><link><target>curator</target></link>.<extension extension_name='ref'><template><target>cite journal</target><arg name="author">Adler D<space/></arg><arg name="title">Darwin's Illness<space/></arg><arg name="journal">Isr J Med Sci<space/></arg><arg name="volume">25<space/></arg><arg name="issue">4<space/></arg><arg name="pages">218–21<space/></arg><arg name="year">1989<space/></arg><arg name="pmid">2496051</arg></template></extension></paragraph><heading level='2'>Research</heading><paragraph>Several experimental treatments have shown promise in animal models. These include inhibitors of<space/><link><target>2,3-oxidosqualene</target><part>oxidosqualene</part></link><space/><link><target>cyclase</target></link><space/>and<space/><link><target>squalene synthase</target></link>,<extension extension_name='ref' name="Grupo">Scientific Working Group on Chagas Disease [April 2005] (July 2007). Guhl F, Lazdins-Helds JK (eds.):<space/><link type='external' href='http://www.who.int/tdr/publications/publications/pdf/swg_chagas.pdf'>''Reporte del grupo de trabajo cientfico sobre la enfermedad de Chagas''</link><space/><template><target>Wayback</target><arg name="date">20081217000134</arg><arg name="url">http://www.who.int/tdr/publications/publications/pdf/swg_chagas.pdf</arg><arg name="df">yes</arg></template><space/>(in Spanish). Geneva: WHO. Retrieved on 29 August 2008.<space/><link type='external' href='http://www.who.int/tdr/diseases/chagas/swg_chagas.pdfExecutive'>summary in English</link></extension><extension extension_name='ref'><template><target>cite journal</target><arg name="author">Urbina JA, Concepcion JL, Rangel S, Visbal G, Lira R<space/></arg><arg name="title">Squalene synthase as a chemotherapeutic target in ''Trypanosoma cruzi'' and ''Leishmania mexicana''<space/></arg><arg name="journal">Mol Biochem Parasitol<space/></arg><arg name="volume">125<space/></arg><arg name="issue">1–2</arg><arg name="pages">35–45<space/></arg><arg name="year">2002<space/></arg><arg name="pmid">12467972<space/></arg><arg name="doi"><space/>10.1016/S0166-6851(02)00206-2</arg><arg name="url">http://linkinghub.elsevier.com/retrieve/pii/S0166685102002062</arg></template></extension><space/><link><target>cysteine protease</target></link><space/>inhibitors,<extension extension_name='ref' name="Grupo"></extension><extension extension_name='ref'><template><target>cite journal</target><arg name="author">Engel JC, Doyle PS, Hsieh I, McKerrow JH<space/></arg><arg name="title">Cysteine Protease Inhibitors Cure an Experimental ''Trypanosoma cruzi'' Infection<space/></arg><arg name="journal">J Exp Med<space/></arg><arg name="volume">188<space/></arg><arg name="issue">4<space/></arg><arg name="pages">725–34<space/></arg><arg name="date">August 1998<space/></arg><arg name="pmid">9705954<space/></arg><arg name="pmc">2213346</arg><arg name="doi"><space/>10.1084/jem.188.4.725</arg><arg name="url">http://www.jem.org/cgi/pmidlookup?view</arg></template></extension><space/><link><target>dermaseptin</target><trail>s</trail></link><space/>collected from frogs in the genus<space/><italics><link><target>Phyllomedusa</target></link></italics><space/>(<italics><link><target>Phyllomedusa oreades</target><part>P. oreades</part></link></italics><space/>and<space/><italics><link><target>Phyllomedusa distincta</target><part>P. distincta</part></link></italics>),<extension extension_name='ref'><template><target>cite journal</target><arg name="author">Brand GD, Leite JR, Silva LP<space/></arg><arg name="title">Dermaseptins from ''Phyllomedusa oreades'' and ''Phyllomedusa distincta''. Anti-''Trypanosoma cruzi'' activity without cytotoxicity to mammalian cells<space/></arg><arg name="journal">[[Journal of Biological Chemistry|J Biol Chem]]<space/></arg><arg name="volume">277<space/></arg><arg name="issue">51</arg><arg name="pages">49332–40<space/></arg><arg name="date">December 2002<space/></arg><arg name="pmid">12379643<space/></arg><arg name="doi">10.1074/jbc.M209289200<space/></arg><arg name="url">http://www.jbc.org/cgi/pmidlookup?view</arg></template></extension><space/>the<space/><link><target>sesquiterpene lactone</target></link><space/>dehydroleucodine (DhL), which affects the growth of cultured<space/><link><target>epimastigote</target></link>-phase<space/><italics>Trypanosoma cruzi</italics>,<extension extension_name='ref'><template><target>cite journal</target><arg name="author">Brengio SD, Belmonte SA, Guerreiro E, Giordano OS, Pietrobon EO, Sosa MA<space/></arg><arg name="title">The sesquiterpene lactone dehydroleucodine (DhL) affects the growth of cultured epimastigotes of ''Trypanosoma cruzi''</arg><arg name="journal">J Parasitol<space/></arg><arg name="volume">86<space/></arg><arg name="issue">2<space/></arg><arg name="pages">407–12<space/></arg><arg name="date">April 2000<space/></arg><arg name="pmid">10780563<space/></arg><arg name="url"></arg><arg name="doi">10.1645/0022-3395(2000)086[0407:TSLDDA]2.0.CO;2<space/></arg><arg name="issn">0022-3395</arg></template></extension><space/>inhibitors of<space/><link><target>purine</target></link><space/>uptake,<extension extension_name='ref' name="Grupo"></extension><space/>and inhibitors of enzymes involved in<space/><link><target>trypanothione</target></link><space/>metabolism.<extension extension_name='ref'><template><target>cite journal</target><arg name="author">Fairlamb AH, Cerami A<space/></arg><arg name="title">Metabolism and functions of trypanothione in the Kinetoplastida<space/></arg><arg name="journal">[[Annual Reviews|Annu Rev Microbiol]]<space/></arg><arg name="volume">46<space/></arg><arg name="pages">695–729<space/></arg><arg name="year">1992<space/></arg><arg name="pmid">1444271</arg><arg name="doi">10.1146/annurev.mi.46.100192.003403<space/></arg><arg name="url">http://arjournals.annualreviews.org/doi/abs/10.1146/annurev.mi.46.100192.003403?url_ver</arg></template></extension><space/>Hopefully, new drug targets may be revealed following the sequencing of the<space/><italics>T. cruzi</italics><space/><link><target>genome</target></link>.<extension extension_name='ref' name="ElSayed2005"><template><target>cite journal</target><arg name="author">El-Sayed NM, Myler PJ, Bartholomeu DC</arg><arg name="title">The genome sequence of ''Trypanosoma cruzi'', etiologic agent of Chagas disease<space/></arg><arg name="journal">[[Science (journal)|Science]]<space/></arg><arg name="volume">309</arg><arg name="issue">5733<space/></arg><arg name="pages">409–15<space/></arg><arg name="date">July 2005<space/></arg><arg name="pmid">16020725<space/></arg><arg name="doi">10.1126/science.1112631<space/></arg><arg name="url">http://www.sciencemag.org/cgi/pmidlookup?view</arg><arg name="bibcode">2005Sci...309..409E</arg></template></extension></paragraph><paragraph>Chagas disease has a serious economic impact on the United States and the world. The cost of treatment in the United States is estimated to be $900 million annually, which includes hospitalization and medical devices such as pacemakers. The global cost is estimated at $7 billion.<extension extension_name='ref'><template><target>cite journal</target><arg name="author">Schmuñis G</arg><arg name="title">Status of and cost of Chagas disease worldwide</arg><arg name="journal">The Lancet infectious diseases</arg><arg name="date">April 2013</arg><arg name="volume">13</arg><arg name="issue">4</arg><arg name="pages">283–4</arg><arg name="pmid">23395247</arg><arg name="doi">10.1016/S1473-3099(13)70032-X</arg></template></extension></paragraph><paragraph><link><target>Megazol</target></link><space/>in a study seems more active against Chagas than benznidazole but has not been studied in humans.<extension extension_name='ref'><template><target>cite journal</target><arg name="doi"><space/>10.1128/AAC.05135-11<space/></arg><arg name="journal"><space/>Antimicrob. Agents Chemother<space/></arg><arg name="date"><space/>2012<space/></arg><arg name="volume"><space/>56<space/></arg><arg name="issue"><space/>1<space/></arg><arg name="pages"><space/>115–123<space/></arg><arg name="title"><space/>Activation of Benznidazole by Trypanosomal Type I Nitroreductases Results in Glyoxal Formation<space/></arg><arg name="url"><space/>http://aac.asm.org/content/56/1/115/T1.expansion.html</arg></template></extension><space/><link><target>Fexinidazole</target></link>, an old drug rediscovered for this purpose is being tested in phase 2 clinical trials.<extension extension_name='ref'>http://outbreaknewstoday.com/chagas-drug-fexinidazole-goes-into-phase-ii-trials-81914/</extension><space/>A Chagas vaccine (TcVac3) has been found to be effective in mice with plans for studies in<space/><link><target>dog</target><trail>s</trail></link>. It is hoped that it will be commercially available by 2018.<extension extension_name='ref'><template><target>cite web</target><arg name="title">Potential Chagas vaccine candidate shows unprecedented efficacy</arg><arg name="url">http://www.sciencedaily.com/releases/2013/03/130326194104.htm<space/></arg><arg name="publisher">ScienceDaily</arg><arg name="accessdate">12 January 2015</arg><arg name="date">March 26, 2013</arg></template></extension></paragraph><heading level='2'>See also</heading><list type='bullet'><listitem><link><target>Drugs for Neglected Diseases Initiative</target></link></listitem><listitem><link><target>Chagas: Time to Treat campaign</target></link></listitem><listitem><link><target>Gefek</target><part>Association for the Promotion of Independent Disease Control in Developing Countries</part></link></listitem></list><heading level='2'>References</heading><preblock><preline><template><target>Reflist</target><arg>2</arg></template></preline></preblock><heading level='2'>Further reading</heading><paragraph><template><target>refbegin</target></template></paragraph><list type='bullet'><listitem><template><target>cite journal</target><arg name="title"><space/>Blood donor screening for Chagas disease — (United States, 2006–2007)<space/></arg><arg name="journal">[[Morbidity and Mortality Weekly Report]]<space/></arg><arg name="date">23 February 2007<space/></arg><arg name="volume">56<space/></arg><arg name="issue">7<space/></arg><arg name="pages">141–43<space/></arg><arg name="url">http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5607a2.htm<space/></arg><arg name="pmid">17318113</arg></template></listitem><listitem><template><target>cite journal</target><arg name="vauthors">Franco-Paredes C, Von A, Hidron A, etal<space/></arg><arg name="title">Chagas disease: an impediment in achieving the Millennium Development Goals in Latin America<space/></arg><arg name="journal">BMC International Health and Human Rights<space/></arg><arg name="volume">7<space/></arg><arg name="page">7<space/></arg><arg name="year">2007<space/></arg><arg name="pmid">17725836</arg><arg name="doi"><space/>10.1186/1472-698X-7-7<space/></arg><arg name="pmc">2034380</arg></template></listitem><listitem><template><target>cite journal</target><arg name="author"><space/>[[Peter Hotez|Hotez PJ]], Dumonteil E, Woc-Colburn L, et al<space/></arg><arg name="date">29 May 2012<space/></arg><arg name="title">Chagas disease: 'The new HIV/AIDS of the Americas'<space/></arg><arg name="journal">[[PLoS Neglected Tropical Diseases]]<space/></arg><arg name="volume">6<space/></arg><arg name="issue">5<space/></arg><arg name="pages">e1498<space/></arg><arg name="doi">10.1371/journal.pntd.0001498<space/></arg><arg name="pmid">22666504<space/></arg><arg name="pmc">3362306<space/></arg></template><space/>An editorial.</listitem><listitem><template><target>cite journal</target><arg name="year"><space/>1999<space/></arg><arg name="title"><space/>International symposium to commemorate the 90th anniversary of the discovery of Chagas disease (Rio de Janeiro, April 11–16, 1999)<space/></arg><arg name="journal">Memorias do Instituto Oswaldo Cruz<space/></arg><arg name="volume"><space/>94<space/></arg><arg name="issue"><space/>Suppl. I<space/></arg><arg name="url">http://www.scielo.br/scielo.php?script</arg></template><space/>A special issue of the<space/><italics>Memrias do Instituto Oswaldo Cruz</italics>, covering all aspects of Chagas Disease</listitem><listitem><template><target>cite book</target><arg name="author">Miles MW, Tyler KM</arg><arg name="title">American trypanosomiasis<space/></arg><arg name="publisher">Kluwer Academic<space/></arg><arg name="location">Boston<space/></arg><arg name="year">2003<space/></arg><arg name="isbn">978-1-4020-7323-6<space/></arg><arg name="oclc">50685296<space/></arg><arg name="url">https://books.google.com/?id</arg></template></listitem></list><paragraph><template><target>refend</target></template></paragraph><heading level='2'>External links</heading><paragraph><template><target>commons category</target></template></paragraph><list type='bullet'><listitem><template><target>dmoz</target><arg>Health/Conditions_and_Diseases/Infectious_Diseases/Parasitic/Chagas_Disease</arg><arg>Chagas disease</arg></template></listitem><listitem><link type='external' href='http://www.cdc.gov/chagas/'>Chagas information</link><space/>at the U.S.<space/><link><target>Centers for Disease Control</target></link></listitem><listitem><link type='external' href='http://www.dndi.org/diseases/chagas.html'>Chagas information</link><space/>from the<space/><link><target>Drugs for Neglected Diseases initiative</target></link></listitem><listitem><link type='external' href='http://www.ibiology.org/ibioseminars/microbiology/norma-andrews-part-1.html'>Norma Andrews's seminar: ''Trypanosoma cruzi'' and Chagas Disease</link></listitem><listitem><link type='external' href='http://www.unhco.org/chagas-disease//'>UNHCO site on Chagas Disease</link></listitem><listitem><link type='external' href='https://www.iamat.org/risks/chagas-disease//'>Chagas Disease information for travellers from IAMAT (International Association for Medical Assistance to Travellers)</link></listitem></list><paragraph><template><target>Diseases of Poverty</target></template><template><target>Protozoal diseases</target></template></paragraph><paragraph><template><target>DEFAULTSORT:Chagas Disease</target></template><link><target>Category:Zoonoses</target></link><link><target>Category:Parasitic infestations, stings, and bites of the skin</target></link><link><target>Category:Insect-borne diseases</target></link><link><target>Category:Neglected diseases</target></link><link><target>Category:Protozoal diseases</target></link><link><target>Category:Tropical diseases</target></link><link><target>Category:Endemic diseases</target></link><link><target>Category:RTT</target></link></paragraph></article>